This week, as Quebec moved towards paying for in vitro fertilization [1] with the goal of reducing expensive and risky multiple births (which may [2] or may not [3] work), it was hard to find a singleton in the world of biotech.
Twin diagnostics projects were born this week as Warnex, the Montreal Heart Institute & CEPMED announced ; and to combat childhood diseases.
Vancouver-based Forbes Medi-Tech , as Pharmachem expressed interest in topping a prior bid by MHT [4].
Finally, the Canadian industry as a whole got a mediocre second fiscal quarter to match 2010’s first mediocre quarter [5], though Wayne Schnarr found some optimism in recent regulatory successes.
Stay tuned for this week’s multitude of developments at The Cross-Border Biotech Blog [6] and @crossborderbio [7] on Twitter.